Literature DB >> 15299851

Comparison of ternary complexes of Pneumocystis carinii and wild-type human dihydrofolate reductase with coenzyme NADPH and a novel classical antitumor furo[2,3-d]pyrimidine antifolate.

V Cody1, N Galitsky, J R Luft, W Pangborn, A Gangjee, R Devraj, S F Queener, R L Blakley.   

Abstract

The novel furopyrimidine N-(4-{N-[(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)methyl]methylamino}benzoyl)-L- glutamate (MTXO), a classical antifolate with antitumor activity comparable to that of methotrexate (MTX), has been studied as inhibitor-cofactor ternary crystal complexes with wild-type Pneumocystis carinii (pc) and recombinant human wild-type dihydrofolate reductase (hDHFR). These structural data provide the first direct comparison of the binding interactions of the same antifolate inhibitor in the active site for pc and human DHFR. The human ternary DHFR complex crystallizes in the rhombohedral space group R3 and is isomorphous to the ternary complex reported for a gamma-tetrazole methotrexate analogue, MTXT. The pcDHFR complex crystallizes in the monoclinic space group P2(1) and is isomorphous to that reported for a trimethoprim (TMP) complex. Interpretation of difference Fourier electron-density maps for these ternary complexes revealed that MTXO binds with its 2,4-diaminofuropyrimidine ring interacting with Glu32 in pc and Glu30 in human DHFR, as observed for MTXT. The presence of the 6-5 furopyrimidine ring instead of the 6-6 pteridine ring results in a different bridge conformation compared with that of MTXT. The bridge torsion angles for MTXO, i.e. C(4a)-C(5)-C(8)-N(9) and C(5)-C(8)-N(9)-C(1'), are -156.5/51.9 degrees and -162.6/51.8 degrees, respectively for h and pc, compared with -146.8/57.4 degrees for MTXT. In each case, the p-aminobenzoylglutamate conformation is similar to that observed for MTXT. In the pcDHFR complex, the active-site region is conserved and the additional 20 residues in the sequence compared with the human enzyme are located in external loop regions. There is a significant change in the nicotinamide ribose conformation of the cofactor which places the nicotinamide O atom close to the 4NH(2) group of MTXO (2.7 A), a shift not observed in hDHFR structures. As a consequence of this, there is a loss of a hydrogen bond between the nicotinamide carbonyl group and the backbone of Ala12 in pcDHFR. In the human ternary complexes, the cofactor NADPH is bound with a more extended conformation, and the nicotinamide O atom makes a 3.5 A contact with the 4NH(2) group of MTXO. Although the novel classical antifolate MTXO is not highly active against pcDHFR, there are correlations between its binding interactions consistent with its lower potency as an inhibitor of h and pcDHFR compared with MTX.

Entities:  

Year:  1997        PMID: 15299851     DOI: 10.1107/S090744499700509X

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  11 in total

1.  CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified cross-validated r(2)-guided region selection (q(2)-GRS) routine and its initial application.

Authors:  Aleem Gangjee; Xin Lin; Lisa R Biondo; Sherry F Queener
Journal:  Bioorg Med Chem       Date:  2010-01-06       Impact factor: 3.641

2.  Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine antifolates.

Authors:  Aleem Gangjee; Yibin Qiu; Wei Li; Roy L Kisliuk
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

3.  Protein pharmacophore selection using hydration-site analysis.

Authors:  Bingjie Hu; Markus A Lill
Journal:  J Chem Inf Model       Date:  2012-03-26       Impact factor: 4.956

4.  Isolation of rat dihydrofolate reductase gene and characterization of recombinant enzyme.

Authors:  Y Wang; J A Bruenn; S F Queener; V Cody
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

5.  Interpretable correlation descriptors for quantitative structure-activity relationships.

Authors:  Benson M Spowage; Craig L Bruce; Jonathan D Hirst
Journal:  J Cheminform       Date:  2009-12-24       Impact factor: 5.514

6.  1,3-Dimethyl-5-(2-methyl-benzyl-idene)pyrimidine-2,4,6(1H,3H,5H)-trione.

Authors:  R Panchatcharam; V Dhayalan; A K Mohanakrishnan; G Chakkaravarthi; V Manivannan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-09-09

7.  1,1',3,3',5,5'-Hexamethyl-spiro-[furo[2,3-d]pyrimidine-6(5H),5'-pyrimidine]-2,2',4,4',6'(1H,3H,1'H,3'H,5'H)-penta-one.

Authors:  Nader Noroozi Pesyan; Saeed Rastgar; Yaser Hosseini
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-05-29

8.  Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents.

Authors:  Aleem Gangjee; Wei Li; Roy L Kisliuk; Vivian Cody; Jim Pace; Jennifer Piraino; Jennifer Makin
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

9.  The Z isomer of 2,4-diaminofuro[2,3-d]pyrimidine antifolate promotes unusual crystal packing in a human dihydrofolate reductase ternary complex.

Authors:  Vivian Cody; Jim Pace; Lu Lin; Aleem Gangjee
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-07-21

10.  Development of a yeast assay for rapid screening of inhibitors of human-derived Pneumocystis carinii dihydrofolate reductase.

Authors:  Liang Ma; Qiuyao Jia; Joseph A Kovacs
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.